2[1]Moennig V. Introduction to classical swine fever: virus, disease and control policy [J]. Vet Microbiol. 2000, 73 (2-3): 93-102.
3[2]VandeputteJ, Chappuis G, Merial, etal. Classical swine fever: the European experience and a guide for infected areas [J]. Rev Sci Tech. 1999, 18 (3): 638-4745.
4[4]Andrew ME, Morfissy CJ, Lenghaus C, et al. Protection of pigs against classical swine fever with DNA-delivered gp55 [J]. Vaccine. 2000, 18 (18):1932-830.
5[5]Rumenapf T, et al. Structural proteins of hog cholera virus expressed by vaccine virus: further characterization and inductionof protedctive immunity [J] . J Virol. 1991, 65: 589-597.
6[6]Konig M, et al. Classical swine fever virus: independent induction of protective immunity by two structural proteins [J]. J Virol. 1995, 69: 6479-6486.
7[7]van Riju P A, et al. Live attenuated pseudorabies virus expressing envelope glycoprotein El of hog cholera virus protect swine against both pseudorabies and hog cholera [J]. J Virol. 1991, 65:2761-2765.
8[8]Moormann RJ, Bouma A, Kramps JA, et al. Development of a classical swine fever subunit marker vaccine and companiondiagnostic test [J]. Vet Microbiol. 2000, 73 (2-3): 209-219.
9[9]Bouma A, De Smit AJ, De Jong MC, et al. Dtermination of the onset of the herd-immunity induced by the E2 sub-unit vaccine against classical swine fever virus [J]. Vaccine. 2000, 18 (14): 1374-81.
10[10]Van Rijn PA, van Gennip HG, Moormann RJ. An experimental marker vaccine and accompanying scrological diagnostic test bothbased on envelope glycoprotein E2 of classical swine fever virus (CSFV)[J]. Vaccine. 1999, 17 (5): 433-4039.
